Is Inovio (Ino) stock set to rebound?
Inovio spinoff Geneos Therapeutics raises $17M to expand cancer treatment study Geneos Therapeutics, a clinical stage biotherapeutics company spun out of Inovio Pharmaceuticals, …
What has Inovio been working on?
Nov 10, 2021 · Inovio's biggest news was that the U.S. Food and Drug Administration (FDA) has given the go-ahead for the initiation of a phase 3 study of COVID-19 vaccine INO-4800. So what
Will Inovio’s VGX-3100 be another winning year for stocks?
Aug 26, 2021 · Shares of Inovio Pharmaceuticals(NASDAQ: INO)were jumping 5.9% higher as of 11:07 a.m. EDT on Thursday after rising as much as 13.6% earlier in the session. The big gain came following Inovio's ...
Which stocks are down 50% from their 52-week highs?
Jan 22, 2016 · Why Inovio Pharmaceuticals (INO) Stock is Up Today Inovio Pharmaceuticals (INO) stock is increasing early Friday afternoon as the company will work with GeneOne Life Science on a vaccine for the...
Why is inovio stock going up?
[Updated: Oct 13, 2021] INO Stock Rise This can be attributed to delays in trials for INO-4800, the company's Covid-19 vaccine candidate.Dec 17, 2021
Is Inovio worth investing?
Inovio Pharmaceuticals, Inc. may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth prospects of INO, demonstrate its potential to underperform the market.
How high is inovio stock expected to go?
30.00Stock Price Forecast The 7 analysts offering 12-month price forecasts for Inovio Pharmaceuticals Inc have a median target of 6.00, with a high estimate of 30.00 and a low estimate of 3.00. The median estimate represents a +83.77% increase from the last price of 3.27.
Why is INO down today?
Shares of Inovio Pharmaceuticals ( INO 6.52% ) were crashing 27.4% as of 10:17 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.Apr 23, 2021
Will inovio get FDA approval?
INOVIO Receives U.S. FDA Authorization to Proceed with INNOVATE Phase 3 Segment for its COVID-19 Vaccine Candidate, INO-4800, in the U.S.Nov 9, 2021
Who owns Inovio Pharmaceuticals?
Top 10 Owners of Inovio Pharmaceuticals IncStockholderStakeShares ownedSSgA Funds Management, Inc.10.49%23,267,928BlackRock Fund Advisors7.05%15,637,463The Vanguard Group, Inc.4.83%10,703,079D. E. Shaw & Co. LP2.70%5,985,5336 more rows
Does Inovio stock go up tomorrow?
NEWS for Inovio Pharmaceuticals, Inc. Click here for more Support & Resistance levels for Inovio Pharmaceuticals, Inc....Munafa value: 40 as on 08 Fri Apr 2022.Strong resistance18Strong resistance17Strong resistance16Strong resistance14Strong resistance1311 more rows
Will Ocugen go up?
Long-term Ocugen stock forecast 2022-2025 The site predicted that the share price could climb over the next year, to $7.2 by March 2023.
What is Nio price target?
The 29 analysts offering 12-month price forecasts for NIO Inc have a median target of 32.97, with a high estimate of 86.67 and a low estimate of 24.11. The median estimate represents a +71.83% increase from the last price of 19.19.
Who did Ino marry?
SaiSai and Ino eventually get married and Ino gave birth their first and only son, Inojin Yamanaka. Sai took his wife's lastname and they run a modern version of the Yamanaka Flower shop together with their son. The couple train their only son who uses his father's techniques as part of the new generation Ino-Shika-Cho.
When did Ino IPO?
Dec. 8, 1998You could have purchased shares of what would later be known as Inovio on Dec. 8, 1998, for a split-adjusted price of $60 per share.May 3, 2020
Is Novavax publicly traded?
Common Stock (NVAX)
What is Prosper's passion?
Is Inovio stock volatile?
Passionate about teaching and learning, he enjoys helping others make better decisions about their finances -- and enjoys it just as much when they return the favor. In his free time, you'll find him curling up with a good book or doing math.
What happened
Inovio's stock will continue to be volatile moving forward. The progress of its COVID-19 program will spell good news for its shareholders, but several things could send its stock tumbling, including the work of other biotechs in the COVID-19 battle. For that reason, Inovio remains a high-risk, high-reward play. Those who can stomach the risk and decide to initiate a position in the company could rack up solid gains between now and the end of the year.
So what
Shares of Inovio Pharmaceuticals (NASDAQ: INO) were jumping 5.9% higher as of 11:07 a.m. EDT on Thursday after rising as much as 13.6% earlier in the session. The big gain came following Inovio's announcement that Brazilian regulators authorized the initiation of a phase 3 clinical study of COVID-19 vaccine candidate INO-4800.
Now what
Inovio had previously announced in June that it was expanding a partnership with Advaccine Biopharmaceuticals Suzhou to conduct global phase 3 studies evaluating INO-4800. The company said at the time that the late-stage testing would primarily be done in Latin America and Asia.
The Motley Fool
It's possible that more catalysts could be on the way for the vaccine stock. Advaccine is moving forward with two clinical trials in China evaluating INO-4800 and Sinovac's CoronaVac COVID-19 vaccine. Inovio also plans to report data for other pipeline candidates later this year.
Inovio's shares are on the mend today
Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community.
What happened
George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since 2013. His primary interests are novel small molecule drugs, next generation vaccines, and cell therapies.
So what
Shares of the clinical-stage biotech Inovio Pharmaceuticals ( NASDAQ:INO) are up by a healthy 20.3%, on abnormally high volume, as of 10:40 a.m. EDT Tuesday. Today's double-digit rally appears to be carryover from CEO Dr. Joseph Kim's presentation yesterday at the H.C. Wainwright 22nd Annual Global Investment Conference.
Now what
Inovio's shares have been under immense pressure for the past three months. In fact, the drugmaker's stock has fallen by nearly 60% relative to its 52-week high posted back in June.
Investors like the biotech's good news from a phase 2 clinical trial
Should investors buy into this latest rally? Inovio is a risky biotech stock to be sure. But there's a decent chance that the biotech could indeed land a sizable award for its COVID-19 vaccine. So, if you're the risk-tolerant type, it might be worthwhile to buy a few shares ahead of this potential catalyst.
What happened
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights
So what
Shares of Inovio Pharmaceuticals ( NASDAQ:INO) were soaring 13.4% higher as of 3:10 p.m. EDT on Friday.
Now what
Positive clinical results nearly always boost biotech stocks, especially for companies like Inovio that don't have approved products yet. And the phase 2 results for VGX-3100 were definitely encouraging. Half of the 20 patients in the study showed clearance of precancerous lesions associated with HPV types 16/18.
In an interview, Inovio Pharmaceuticals' CEO talked up the company's efforts to develop a COVID-19 vaccine
It's important to keep in mind that the results Inovio announced on Thursday were only interim results. The phase 2 study is still under way and won't wrap up until next year.
What happened
A Fool since 2019, Prosper's writing focuses primarily on the healthcare sector. Passionate about teaching and learning, he enjoys helping others make better decisions about their finances -- and enjoys it just as much when they return the favor. In his free time, you'll find him curling up with a good book or doing math.
So what
Shares of Inovio Pharmaceuticals ( NASDAQ:INO) were up by 21.4% as of 3:12 p.m. EDT on Friday. The market is likely responding to a Thursday evening CNBC interview of the company's CEO, Dr. Joseph Kim.
Now what
Inovio recently kicked off a phase 1 clinical trial to test the safety of its investigational COVID-19 vaccine, INO-4800. The trial -- which will involve up to 40 healthy adult volunteers -- will also test the vaccine's ability to trigger an immune response in the body.
